Arcus Biosciences Inc.

ARQT

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Driehaus Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 2,562,445Value: $74.4M

# Signal Note: Driehaus Initiates $74.4M Position in ARQT Driehaus' entry suggests conviction in Arcus' pipeline, likely centered on domvanalimab (anti-TIGIT) either as monotherapy or in combination strategies—the company has Phase 2 data in multiple solid tumors and partnerships with established pharma that could de-risk development. The position sizing ($74.4M across ~2.6M shares) indicates a meaningful commitment from a growth-focused allocator, potentially ahead of upcoming clinical readouts or partnership announcements in 2024-2025.

More ARQT Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

PTN1 fund WLDN1 fund LASR1 fund ONTO1 fund VALE1 fund TNDM1 fund TKO1 fund TNL1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: